Early autologous stem cell transplantation for chronic lymphocytic leukemia: Long-term follow-up of the German CLL study group CLL3 trial

Blood

Volumn 119, Issue 21, 2012, Pages 4851-4859

  Dreger, Peter ^a   Döhner, Hartmut ^b   McClanahan, Fabienne ^a   Busch, Raymonde ^c   Ritgen, Matthias ^d   Greinix, Hildegard ^e   Fink, Anna Maria ^f   Knauf, Wolfgang ^g   Stadler, Michael ^h   Pfreundschuh, Michael ⁱ   Dührsen, Ulrich ^j   Brittinger, Günter ^j   Hensel, Manfred ^a   Schetelig, Johannes ^k   Winkler, Dirk ^b   Bühler, Andreas ^b   Kneba, Michael ^d   Schmitz, Norbert ^l   Hallek, Michael ^f   Stilgenbauer, Stephan ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Oncology Care   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC RISK; GERMANY; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; RETROSPECTIVE STUDY; RISK FACTOR; STEM CELL MOBILIZATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 84861498523     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-378505     Document Type: Article

References (28)

1. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82(4): 1366-1376. (Pubitemid 23254015)
2. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389-4396. (Pubitemid 41775953)
3. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol. 1994;12(4):748- 758.
4. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer. 1998; 77(12):2291-2297. (Pubitemid 28263956)
5. Itälä M, Pelliniemi T-T, Rajamäki A, Remes K. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant. 1997;19(7):647-651. (Pubitemid 27182486)
6. Pavletic ZS, Biermann PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998;9(9):1023-1026. (Pubitemid 28496713)
7. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia. 1998;12(11): 1699-1707. (Pubitemid 28502488)
8. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001;15(3):445- 451.
9. Milligan DW, Fernandes S, Dasgupta R, et al. Autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Results of the MRC Pilot Study. Blood. 2005;105(1):397- 404.
10. Michallet M, Dreger P, Sutton L, et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood. 2011;117(5):1516- 1521.
11. Sutton L, Chevret S, Tournilhac O, et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter randomized controlled trial. Blood. 2011;117(23):6109- 6119.
12. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088. (Pubitemid 46211313)
13. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975- 980.
14. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
15. Brion A, Mahe B, Kolb B, et al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplant. 2012;47(4):542-548.
16. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052- 1057.
17. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a sub-group at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93(5):1732-1737. (Pubitemid 29102502)
18. Dreger P, Viehmann K, von Neuhoff N, et al. A prospective study of positive/negative ex-vivo B cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol. 2000;28(10):1187- 1196.
19. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 2003;101(5):2049- 2053.
20. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 2004;103(7): 2850-2858. (Pubitemid 38393051)
21. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
22. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
23. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-1416. (Pubitemid 34864299)
24. Ritgen M, Böttcher S, Stilgenbauer S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: Results from the GCLLSG CLL3X trial. Leukemia. 2008;22(7):1377-1386. (Pubitemid 352006082)
25. Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004;103(1):363-365. (Pubitemid 38029961)
26. Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996;88(6):2228- 2235.
27. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer. 2010;10(1):37-50.
28. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591-594.